Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CHMFL-EGFR-202 是一种有效、不可逆的表皮生长因子受体 (EGFR) 突变型激酶抑制剂, 对耐药突变型 EGFR T790M 和 WT EGFR 激酶作用的 IC50 分别为 5.3 nM 和 8.3 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,290 | 现货 | ||
2 mg | ¥ 1,930 | 现货 | ||
5 mg | ¥ 2,990 | 现货 | ||
10 mg | ¥ 4,390 | 现货 | ||
25 mg | ¥ 6,910 | 现货 | ||
50 mg | ¥ 9,480 | 现货 | ||
100 mg | ¥ 12,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,460 | 现货 |
产品描述 | CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases). |
靶点活性 | EGFR (T790M):5.3 nM, EGFR:8.3 nM, BLK:8.1 nM, MEK1:161 nM, BTK:24.5 nM, ERB4:3.2 nM, BMX:111 nM, ErbB2:8.1 nM |
体外活性 | CHMFL-EGFR-202 exhibits ∼10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 potently inhibits EGFR primary mutants (L858R, del19) and drug-resistant mutant L858R/T790M. CHMFL-EGFR-202 displays strong binding affinities against wild-type, L861Q, G719C/S, L858R/T790M, L858R, and T790M among EGFR wild-type and mutant kinases. CHMFL-EGFR-202 also exhibits strong binding affinities against BLK, BMX, BTK, ERBB2, ERBB4, LOK, MEK1, and MEK5 kinases (percent of control score less than 1% at 1 μM). CHMFL-EGFR-202 strongly inhibits BLK, BTK, ERBB2 and ERBB4 (IC50s: of 8.1 nM, 24.5 nM, 8.1 nM and 3.2 nM). CHMFL-EGFR-202 moderately inhibits BMX and MEK1 kinases (IC50s: 111.0 nM and 161.0 nM)[1]. |
分子量 | 489.96 |
分子式 | C25H24ClN7O2 |
CAS No. | 2089381-40-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (91.84 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.041 mL | 10.2049 mL | 20.4098 mL | 51.0246 mL |
5 mM | 0.4082 mL | 2.041 mL | 4.082 mL | 10.2049 mL | |
10 mM | 0.2041 mL | 1.0205 mL | 2.041 mL | 5.1025 mL | |
20 mM | 0.102 mL | 0.5102 mL | 1.0205 mL | 2.5512 mL | |
50 mM | 0.0408 mL | 0.2041 mL | 0.4082 mL | 1.0205 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CHMFL-EGFR-202 2089381-40-6 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR CHMFL-EGFR 202 CHMFL-EGFR202 CHMFLEGFR202 CHMFL EGFR 202 Inhibitor inhibitor inhibit